Although the mechanism by which PIDD promotes cell cycle arrest and drug resistance is not well understood, the significance of mutations in the p53 tumor suppressor or overexpression of anti-apoptotic Bcl-2 family proteins is implicated in malignant transformation and therapeutic resistance. This evidence concerns the gene PIDD1 and neoplasm.